Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients

Background SARS-CoV-2, the cause of coronavirus disease 2019 (COVID-19), is associated with respiratory-related morbidity and mortality. Assays to detect virus-specific antibodies are important to understand the prevalence of infection and the course of the immune response. Methodology Quantitative measurements of plasma or serum antibodies by luciferase immunoprecipitation assay systems (LIPS) to the nucleocapsid and spike proteins were analyzed in 100 cross-sectional or longitudinal samples from SARS-CoV-2-infected patients. A subset of samples was tested with and without heat inactivation. Results Fifteen or more days after symptom onset, antibodies against SARS-CoV-2 nucleocapsid protein showed 100% sensitivity and 100% specificity, while antibodies to spike protein were detected with 91% sensitivity and 100% specificity. Neither antibody levels nor the rate of seropositivity were significantly reduced by heat inactivation of samples. Analysis of daily samples from six patients with COVID-19 showed anti-nucleocapsid and spike antibodies appearing between day 8 to day 14 after initial symptoms. Immunocompromised patients generally had a delayed antibody response to SARS-CoV-2 compared to immunocompetent patients. Conclusions Antibody to the nucleocapsid protein of SARS-CoV-2 is more sensitive than spike protein antibody for detecting early infection. Analyzing heat-inactivated samples by LIPS is a safe and sensitive method for detecting SARS-CoV-2 antibodies.

Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing 62 coronavirus disease 2019 , were first reported in China [1][2][3][4]. The major clinical 63 feature of COVID-19 SARS-CoV-2 is virus-associated pneumonitis [5][6][7]. Unlike other highly several groups have reported serological diagnostic tests using the nucleocapsid and/or spike 80 protein from SARS-CoV-2 by ELISA [11,16,17], immunofluorescence [18] and even a lateral 81 flow test [19]. One study that used ELISA to measure only antibodies to the nucleocapsid 82 protein found that patients become seropositive 10-18 days after the onset of symptoms [16]. A 83 commercial ELISA using the spike protein demonstrated that IgG antibodies were detectable at a 84 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020 median of 14 days after onset of symptoms [17]. To et al. examined antibodies against both the 85 spike and nucleocapsid by ELISA in a small number of samples and found that IgG antibodies 86 against the nucleocapsid protein were generally detectable at about the same time as antibodies 87 to the spike protein [11]. Despite these findings, further studies are needed to better understand 88 antibody dynamics in persons infected with SARS-CoV-2 to determine the most sensitive and 89 specific antibody assays, and to use these antibody-based tests to determine seroprevalence in 90 different populations. In addition, it is currently unknown whether the viral RNA that has been 91 detected in the blood [11,13] indicates the presence of infectious virus, but this has the potential 92 to be a safety hazard for health care workers, clinical laboratory technicians and researchers 93 analyzing serology in persons infected with SARS-CoV-2. Thus, a sensitive and specific 94 antibody assay using heat treated plasma or serum may enhance safety when working with these 95 fluids. 96 We and others have employed a liquid phase immunoassay technology termed Luciferase 97 Immunoprecipitation Systems (LIPS) to measure antibodies against many different viruses, to 98 stratify infected patients based on the level of their antibodies, and for virus discovery [20]. range up to 6 log10 for some antigens and require < 5 ul of plasma or sera for testing. Here 106 recombinant nucleocapsid and spike protein from SARS-CoV-2 as antigens in LIPS assays were 107 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020 used to measure antibodies in patients with COVID-19 from four geographically disparate 108 locations across the United States. The LIPS assay showed high sensitivity and specificity for 109 detecting SARS-CoV-2 antibodies and demonstrated that nucleocapsid antibodies emerge before 110 spike antibodies. Moreover, as there are potential safety issues related to the presence of SARS-111 CoV-2 RNA in blood, we show that heat inactivation of plasma at 56˚C for 30 min does not 112 significantly reduce the sensitivity of the LIPS assay and thus allows testing to be performed 113 more safely.

Characteristics of the patients with COVID-19
116 This retrospective study analyzed both cross-sectional and longitudinal blood samples collected  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020 from the NIH Clinical Center, Bethesda, MD were confirmed positive for SARS-CoV-2 RNA. In 131 the case of the NIH samples, serial daily blood drawn samples (n=68) were available covering 0-132 20 days from symptom onset.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10. 1101/2020 comparing antibody detection using pGAUS3-Spike-∆2 and pGAUS3-Spike showed similar 154 results and the former construct was not used further.

155
Nucleocapsid and spike protein-light emitting plasmid constructs were transfected into 156 Cos1 cells with Fugene-6 and lysates were harvested 48 hours later to obtain crude cell extracts.

157
For testing, heat-inactivated serum or plasma samples were diluted 1:10 in assay buffer A 158 (20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1% Triton X-100) and 10 µl of the diluted 159 sample were then tested in a 96-well microtiter plate as described [25]. After incubation at room 160 temperature for one hour, the mixture was transferred to a microtiter filter plate containing  For some of the data percentages for categorical variables, mean and range, geometric mean plus 171 95% CI were used to describe the data. Wilcoxon signed rank were used for statistical analysis. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10. 1101/2020 Patients with COVID-19 were located in four geographically distinct locations across the United 176 States and included 35 SARS-CoV-2 cases confirmed by PCR, 10 subjects with COVID-19-like 177 symptoms or household contacts of persons with COVID-19 (not tested by PCR), and 32 blood 178 donors who donated samples before 2018 used as controls (Table 1). The majority of the SARS-

179
CoV-2 PCR-confirmed cases were male (87%) and the median age was 44 years (range, 32-50 180 years). A subset of the SARS-CoV-2 PCR-confirmed cases had one or more risk factors 181 including heart disease, lung disease, diabetes, and/or they were immunocompromised. Two This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10. 1101/2020 from the mean plus four standard deviations (125,000 LU) and the mean plus three standard 199 deviations (45,000 LU) of the blood donor controls, respectively.  Evaluation of samples collected at <14 days after onset of symptoms showed reduced 218 sensitivity, but specificity was maintained. The sensitivity for antibody to the nucleocapsid 219 protein at this time point was 51% (33/65) with antibodies detected in 1/6 samples from UCSD, 220 5/9 from UW, 3/6 from EH and 24/44 from NIH (Figure 1, orange dots). Analysis of spike 221 for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10. 1101/2020 antibodies of samples collected at <14 days after onset of symptoms showed a sensitivity of 43% 222 (28/65) with antibody detected in 0/6 samples from UCSD, 4/9 samples from UW, 2/6 from EH 223 and 22/44 from NIH. Taken together, our findings indicate that detection of antibodies against 224 the nucleocapsid protein is more sensitive than detection of antibodies against the spike protein, 225 and that nucleocapsid antibodies generally appear earlier than spike antibodies.

226
In addition to the SARS-CoV-2 PCR-confirmed patients, suspected cases of COVID-19 227 from EH were also analyzed for seropositivity. Nine of the ten suspected cases without viral PCR 228 confirmation, that showed symptoms compatible with COVID-19 collected between January and 229 February 2020, were seronegative for both nucleocapsid and spike antibodies (Figure 1). 230 Interestingly, one case from March 2020 from a person who was a household contact with a 231 SARS-CoV-2 PCR+ patient, was seropositive for both nucleocapsid and spike antibodies.

232
Since there is interest in using serological assays to assess current and historical   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020 response, none of the immunocompromised patients died. Overall, the results with this small 268 group of patients suggests that immunocompromised patients generally have a more attenuated 269 and/or delayed antibody response to SARS-CoV-2 than immunocompetent patients. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10. 1101/2020 other published assays [11,[16][17][18][19]]. An analysis of longitudinal plasma samples showed that 292 antibodies against the nucleocapsid and spike proteins appeared about the same time between 293 day 8 and day14 after the onset of symptoms. Only one study to date has examined antibodies 294 separately against the nucleocapsid protein and spike protein [11] and our findings are in general 295 agreement. COVID-19 patient plasma samples obtained ≥14 days after symptom onset showed 296 that the LIPS assay for antibodies against the nucleocapsid and spike protein had 100% and 94% 297 sensitivity, respectively, with 100% specificity for both antibodies. Additional studies using this 298 high-throughput, highly quantitative LIPS assay may also help determine whether the relative This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10. 1101/2020 immunocompromised NIH patients exhibited a slower rise in antibody levels with a plateau at 315 lower levels compared to the immunocompetent patients, and two patients did not become This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020 performance. Nonetheless, our current assay provides highly quantitative results with a high 338 degree of sensitivity and specificity and should be useful for larger seroepidemiologic studies. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10. 1101/2020 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020.    This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.